StockVS

Schrödinger, Inc. (SDGR) Aandelenanalyse

Gezondheidszorg

Schrödinger, Inc.

$13.15

$-0.15 (-1.13%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

Schrödinger, Inc. is a specialized enterprise that develops and operates a physics-based computational platform designed to facilitate the discovery of novel molecules for drug development and materials applications across the United States, the Asia-Pacific region, Europe, the Middle East, Africa, and internationally. The company operates within the Healthcare sector, specifically classified under the Health Information Services industry, where it leverages advanced computational chemistry to accelerate the research and development lifecycle for pharmaceutical and biotechnology clients. On a global scale, the organization employs approximately 850 individuals and maintains a market capitalization of $839.39M, while reporting a trailing twelve-month revenue of $255.87M. These valuation and revenue figures position the entity as a significant player in the digital health infrastructure space, indicating a substantial market presence that relies on intellectual property and proprietary software to serve a global client base spanning multiple continents.

Financiële gezondheid

Over the trailing twelve months, the company generated $255.87M in revenue, yet reported a net income of -$103.265M and an EBITDA of -$160.874M, revealing a significant divergence between top-line sales and bottom-line profitability that highlights a substantial operating cost structure or investment in growth initiatives. Despite the negative net income and EBITDA, Schrödinger, Inc. demonstrated strong financial flexibility by generating $99.98M in free cash flow, which suggests the business can fund operations and potentially return capital or invest in R&D without relying on external financing. The company's margin profile presents a complex picture, with a gross margin of 55.7% indicating efficient production and licensing of its software platform, contrasted sharply by an operating margin of -19.7% and a profit margin of -40.4% that reflect high administrative, sales, or research expenses. In terms of leverage, the balance sheet holds $395.46M in cash against $109.31M in debt, resulting in a debt-to-equity ratio of 30.03, which indicates a highly leveraged position relative to equity though the absolute debt burden is manageable given the cash reserves. Liquidity is robust, evidenced by a current ratio of 2.75, which signifies that the company possesses more than two and a half times the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity stands at -26.3% and the return on assets at -13.5%, metrics that reveal that management is currently deploying capital to generate losses, a scenario common in early-stage growth companies but one that signals a lack of immediate profitability on the invested capital base.

Waarderingsbeoordeling

The valuation metrics for Schrödinger, Inc. show a trailing P/E ratio that is N/A due to negative earnings, while the forward P/E is listed at -8.24, implying that the market prices the stock based on future expectations that anticipate a turnaround in earnings trajectory before the next reporting cycle. The price-to-book ratio is 2.30, suggesting that the market values the company at more than double its net asset value, which often indicates a premium assigned to its intangible assets such as proprietary algorithms and data sets. Alternative valuation measures provide further context, with a price-to-sales ratio of 3.28 and an EV/EBITDA of -3.44, figures that suggest the market is willing to pay a significant multiple of sales despite the current lack of profitability, a strategy typical for companies with high growth potential. The stock's recent trading range has been defined by a 52-week high of $27.63 and a 52-week low of $10.95, placing the current price within a wide band that reflects high market volatility and uncertainty regarding future performance. The beta of 1.62 indicates that the stock's price volatility is significantly higher than that of the broader market, moving 62% more than the market average in response to systemic risk factors.

Growth & Income

The company's growth metrics indicate a revenue decline of -1.2% year-over-year, while earnings growth is N/A due to the absence of net income, meaning there is no earnings growth to compare against revenue contraction at this time. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the organization reinvests its entire cash flow and earnings back into the business rather than distributing returns to shareholders. This approach to capital allocation implies that management prioritizes expanding the computational platform and acquiring new clients over providing immediate income to investors. Overall, the growth and income profile is characterized by a contraction in sales revenue and a complete absence of dividend income, reflecting a mature yet still loss-making stage where capital preservation and strategic reinvestment are the primary financial objectives.

Vergelijking met sectorgenoten

Schrödinger, Inc. (SDGR) is actief in de Gezondheidsinformatiediensten-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
Schrödinger, Inc. SDGR $982.58M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

De gemiddelde K/W-verhouding in de Gezondheidsinformatiediensten-sector is 57.5x. Schrödinger, Inc. wordt verhandeld tegen een K/W van N/A.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over Schrödinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$982.58M
K/W-verhouding
N/A
52-weken hoog
$27.63
52-weken laag
$10.95
Gem. Volume
1.32M
Bèta
1.58

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
United States
Werknemers
850